Funding for this research was provided by:
National Cancer Institute (R01CA132115)
U.S. Department of Defense (W81XWH1810605)
Cytodyn Inc (Contract)
Received: 30 April 2020
Accepted: 11 January 2021
First Online: 23 January 2021
Ethics approval and consent to participate
: Animal studies were approved by the Lankenau Institute for Medical Research Institutional Animal Care and Use Committee (IACUC).
: Not applicable
: R.G.P. holds ownership interests in, CytoDyn Inc. and LightSeed, Inc., receives income from the provision of testimony as an expert witness, serves on the advisory boards of Azure Health, and the MD Anderson Cancer Center Breast Cancer SPORE, and holds ownership interests (value unknown) for several patents and submitted patent applications. The other authors declare that they have no conflict of interest.